Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2012

View Archived Issues

New human cellular models of Alzheimer's disease developed

Scientists link new genes to Baraitser-Winter syndrome

In vitro results show potency of novel bispecific HIV-1-neutralizing antibody

OPKO Health attains global license to novel Parkinson's disease candidate

Anthera Pharmaceuticals stops VISTA-16 study

Further data reported on add-on boceprevir therapy in HCV/HIV-coinfected patients

Cellceutix files pre-IND submission for candidate psoriasis drug

Intrepid to conduct phase II trial of candidate acne treatment

MediGene announces additional approvals of topical drug for genital warts

Watson Pharmaceuticals launches new phase III trial

BrainStorm Cell Therapeutics plans stem cell trial in MS

Aradigm obtains clearance for phase III Pulmaquin study

Shionogi identifies new P2X3 and P2X2/3 receptor antagonists

New PI3K inhibitors developed

Novel potential neutropenia therapies developed

Merck & Co. announces new vaccines

Astellas Pharma discloses new inhibitors of IL-2 production and PI3Kdelta

Medivir launches two new phase III TMC-485 studies

Allon Therapeutics advances preclinical work in Parkinson's disease

Amorfix announces new technology acquisition

Immunovaccine and Weill Cornell Medical College join to develop anticocaine vaccine

Tranzyme Pharma and Norgine report topline data on ulimorelin

Reviva Pharmaceuticals kicks off enrollment in phase II RP-5063 trial

DNDi launches phase I trial of drug for sleeping sickness

Phase II results trigger milestone payment to NicOx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.